Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TQ-B3525 in Relapsed/Refractory Mantle Cell Lymphoma
CTR20200773Phase 2Terminated
- Sponsor
- Chia Tai-Tianqing Pharmaceutical Group
- Start
- Apr 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of TQ-B3525 in mantle cell lymphoma (MCL), sponsored by Chia Tai-Tianqing Pharmaceutical Group. Started Apr 2020; status: terminated.
02
Drugs
TQ-B3525
03
Conditions
mantle cell lymphoma (MCL)
Beyond the preview
Go deeper on CTR20200773.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20200773.